Can Hybrid SPECT-CT Overcome the Limitations Associated With Poor Imaging Properties of 131I-MIBG?

Abstract

I-MIBG hybrid SPECT-CT shows high sensitivity and specificity for characterizing adrenal lesions in patients with clinical or biochemical suspicion of pheochromocytoma and is superior to PS and SPECT alone. It will be especially useful in countries where (123)I-MIBG is not available.

Diagnostic Performance of 68Ga-DOTATATE PET/CT, 18F-FDG PET/CT and 131I-MIBG Scintigraphy in Mapping Metastatic Pheochromocytoma and Paraganglioma

“…Although the use of SPECT/CT in 131 I-MIBG would improve the diagnostic certainty in indeterminate lesions and contribute to better diagnostic performance than planar imaging [29,30], it is arguable in our study because 58.8 % (10/17) of patients showed normal scintigraphic finding where application of SPECT/CT in these patients was not required. Furthermore, the number of lesions detected by 131 I-MIBG planar images was so small that could be discretely correlated well to one of the PET/CT, CT or MRI images.…”

Increased MIBG Activity in the Uterine Cervix Due to Menstruation

“…The findings also confirm that pelvic SPECT/CT can overcome many limitations associated with planar imaging and should be considered when the etiology of MIBG activity is equivocal. 14,15 …”

Should every patient diagnosed with a phaeochromocytoma have a 123I‐MIBG scintigraphy?

“…11 123 I-MIBG is superior to 131 I-MIBG due to its shorter half-life, lower radiation exposure and higher sensitivity as it allows single photon emission computed tomography (SPECT) imaging which nowadays can be fused with CT to SPECT/CT for better anatomic correlation. 12 Although there are no definite contraindications for 123 I-MIBG scanning except pregnancy, there are several practical disadvantages of 123 I-MIBG. First, 123 I-MIBG scanning needs a minimum of 24 h between tracer injection and imaging.…”